| Literature DB >> 34305595 |
Yuxin Li1, Zhang Zhang1, Sen Li1, Tingting Yu1, Zhaoqi Jia1.
Abstract
Calcium, as a second messenger, plays an important role in the pathogenesis of cardiovascular diseases (CVDs). The malfunction of calcium signaling in endothelial cells and vascular smooth muscle cells promotes hypertension. In cardiomyocytes, calcium overload induces apoptosis, leading to myocardial infarction and arrhythmias. Moreover, the calcium-calcineurin-nuclear factor of activated T cells (NFAT) pathway is essential for expressing the cardiac pro-hypertrophic gene. Heart failure is also characterized by reduced calcium transient amplitude and enhanced sarcoplasmic reticulum (SR) calcium leakage. Traditional Chinese medicine (TCM) has been used to treat CVDs for thousands of years in China. Because of its multicomponent and multitarget characteristics, TCM's unique advantages in CVD treatment are closely related to the modulation of multiple calcium handling proteins and calcium signaling pathways in different types of cells involved in distinct CVDs. Thus, we systematically review the diverse mechanisms of TCM in regulating calcium pathways to treat various types of CVDs, ranging from hypertrophic cardiomyopathy to diabetic heart disease.Entities:
Keywords: calcium signaling; cardiomyocytes; cardiovascular diseases; endothelial cells; traditional Chinese medicine; vascular smooth muscle cells
Year: 2021 PMID: 34305595 PMCID: PMC8299363 DOI: 10.3389/fphar.2021.682273
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
The mechanism of TCM in the treatment of cardiac hypertrophy through calcium signaling.
| Type of TCM | TCM | Type of study | Type of cell | Mechanism of action | References |
|---|---|---|---|---|---|
| The bioactive ingredients of TCM | Dracocephalum heterophyllum Benth flavonoid |
| Cardiomyocytes | Downregulation of cardiac hypertrophy genes and reducing cell surface area |
|
| Stachydrine |
| Ventricular myocytes | Reducing cAMP levels, inhibiting PKA activation and PLN phosphorylation |
| |
| Tanshinone IIA |
| Ventricular myocytes | Preventing the augment of intracellular calcium transient and inhibiting calcium-mediated calcineurin/NFATc3 pathways |
| |
| Tu-fu-ling flavonoids |
| Cardiomyocytes | Attenuating hypertrophy by restoring the JP2 and RyR2 expressions of cardiomyocytes |
| |
| Smilax glabra flavonoids |
| H9C2 | Inhibiting intracellular calcium release |
| |
| Scutellarin |
| Cardiomyocytes | Alleviating the increment of free intracellular calcium |
|
FIGURE 1TCM and its active ingredients treat CVDs by regulating calcium signaling pathways in cardiomyocytes. ①Matrine; ②Matrine; ③Changrolin, Paeoniflorin monomer, Dehydroevodiamine alkaloid; ④Stachydrine; ⑤Scutellarin, Astragali Radix; ⑥Senkyunolide A, Smilax glabra flavonoids, Baicalein; ⑦Astragalus polysaccharide; ⑧Baicalein; ⑨6-Gin; Astragaloside IV; Wenxin Keli; Qiliqiangxin; Total flavones from AS; ⑩Senkyunolide A; Ligustrazine.
The mechanism of TCM in the treatment of arrhythmia through calcium signaling.
| Type of TCM | TCM | Type of study | Type of cell | Mechanism of action | References |
|---|---|---|---|---|---|
| The bioactive ingredients of TCM | Matrine |
| Cardiomyocytes | Restoring the Ito, recovering the IK1 and the amplitude of [Ca2+]i |
|
| Changrolin |
| Cardiomyocytes | Blocking sodium and calcium channels |
| |
| Paeoniflorin monomer |
| Cardiomyocytes | Blocking |
| |
| Isorhynchophylline |
| Cardiomyocytes | Decreasing action potential duration and inhibiting calcium currents |
| |
| Chinese patent medicine | Wenxin keli |
| Cardiomyocytes | Reducing calcium overload |
|
| Shensong Yangxin |
| Cardiomyocytes | Blocking multiple ion channels |
| |
| Qiliqiangxin |
| Ventricular myocytes | Blocking |
| |
The mechanism of TCM in the treatment of hypertensive heart disease through calcium signaling.
| Type of TCM | TCM | Type of study | Type of cell | Mechanism of action | References |
|---|---|---|---|---|---|
| The bioactive ingredients of TCM | α-Isocubebene |
| VSMCs | Inhibiting calcium flux into VSMC |
|
| Aqueous extract of Pimpinella anisum L. seeds |
| Myocardial cells/VSMCs | Inhibiting calcium influx |
| |
| Berberine |
| VSMCs | Decreasing [Ca2+]i levels and CaM/MLC activity |
| |
| Tetrahydropalmatine |
| VSMCs | Reducing the intracellular Ca2+ release induced vascular tension |
| |
| Tanshinone ⅡA sodium sulfonate |
| VSMCs | Depending on the large conductance calcium-activated potassium (BKCa) channels. |
| |
| Extract of curcuma longa L. |
| VSMCs | Blocking extracellular calcium influx and/or inhibition of intracellular Ca2+ release |
| |
| Chinese Medicine decoction | Danshen and Gegen decoction |
| VSMCs | Blocking [Ca2+]i |
|
FIGURE 2TCM and its active ingredients promote vasodilation and lower blood pressure by regulating calcium signaling pathways in endothelial cells and vascular smooth muscle cells.
The mechanism of TCM in the treatment of heart failure through calcium signaling.
| Type of TCM | TCM | Type of study | Type of cell | Mechanism of action | References |
|---|---|---|---|---|---|
| The bioactive ingredients of TCM | Baicalein |
| H9C2 | Downregulation of phosphorylation of CaMKII and expression of NCX1, upregulation of SERCA2 and RYR2 |
|
| Stachydrine hydrochloride |
| Ventricular myocytes | Improving the calcium transient amplitudes, inhibiting the SR leakage |
| |
| Sophoridine |
| Cardiomyocytes | Upregulation of DHPR and ameliorating cardiac CICR |
| |
| Astragaloside IV |
| Cardiomyocytes | Altering calcium homeostasis, inhibition of calcium influx and promotion of calcium release from SR. |
|
The mechanism of TCM in the treatment of coronary heart disease and myocardial infarction through calcium signaling.
| Type of TCM | TCM | Type of study | Type of cell | Mechanism of action | References |
|---|---|---|---|---|---|
| The bioactive ingredients of TCM | Four main active ingredients derived from Guanxin Shutong capsule |
| Cardiomyocytes | Inhibiting calcium overload |
|
| Chinese Medicine decoction | Modified Yi Qi decoction |
| Myocardial cells | Regulation of apoptotic proteins, cytosolic calcium handling proteins |
|
| Chinese patent medicine | Xin-ke-shu |
| Myocardial cells | Inhibiting calcium overload |
|
FIGURE 3Chemical structures of TCM bioactive components that regulate calcium signaling pathways.
FIGURE 4The heart and blood vessels are two key components of the circulatory system containing various types of cells. TCM can target calcium signaling in endothelial cells, vascular smooth muscle cells, and cardiomyocytes for CVDs treatment.